Synopsis

Sanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push, recent underperformance and the resultant lower valuation are the other factors that have made the company a favourite of analysts.

Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Special Offer on ET Prime

Subscribe to ET Prime – Get Flat 20% Off

View Plans

Special Offer on ET Prime

Subscribe to ET Prime – Get Flat 20% Off

View Plans

Special Offer on ET Prime

Subscribe to ET Prime – Get Flat 20% Off

View Plans

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Read more: EconomicTimes

Share.

Leave A Reply